Gingival Crevicular Fluid Vaspin and Omentin Levels in Type 2 Diabetic Patients With Chronic Periodontitis
Launched by BULENT ECEVIT UNIVERSITY · Sep 8, 2015
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
Adipose tissue produces and releases a variety of inflammatory factors, including adipocytokines , such as adiponectin, leptin, tumor-necrosis factor alpha (TNF-α), interleukin-6 (IL-6), visfatin, vaspin and omentin.These adipokines have widespread effects on carbohydrate and lipid metabolism and appear to play an important role in the pathogenesis of insulin resistance, diabetes, inflammation, wound healing, and immune responses.Recently, studies evaluated the serum vaspin and omentin levels as inflammatory markers in T2DM patients. Based on the above mentioned studies, the present investi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diabetic subjects should have T2DM and had no any known systemic diseases other than T2DM
- • Subjects who had HbA1c levels \< 8% and ≥ 6.5% (well and moderate control)
- • Chronic periodontitis patients had radiographic evidence of bone loss and attachment loss with a minimum of 6 teeth having pocket probing depth (PD) ≥ 5mm in at least 2 different quadrants
- • Control groups were designed as healthy if the full-mouth probing depth (PD) was ≤3mm and bleeding on probing (BOP) score \< %15 at examination and they had no radiographic evidence of alveolar bone loss.
- Exclusion Criteria:
- • Presence of other systemic disorders that could influence the course of periodontal disease; pregnancy, lactation, current and former use of tobacco;
- • Administration of non-steroidal and anti-inflammatory drugs or antibiotic therapies within the previous 6 months;
- • Need for antibiotic prophylaxis for dental treatment and having received non-surgical periodontal treatment within the past 6 months or surgical periodontal treatment within the past 12 months.
- • Subjects who had body mass index (BMI) \>24.9 kg /m2
About Bulent Ecevit University
Bülent Ecevit University is a distinguished academic institution located in Zonguldak, Turkey, committed to advancing medical research and innovation. As a clinical trial sponsor, the university leverages its robust academic resources and interdisciplinary expertise to conduct high-quality research aimed at improving patient care and healthcare outcomes. The institution fosters collaboration among researchers, clinicians, and industry partners, ensuring adherence to ethical standards and regulatory compliance while promoting the translation of scientific discoveries into practical applications. Through its clinical trials, Bülent Ecevit University strives to contribute valuable insights to the medical community and enhance the overall health landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Umut Ballı, DDS
Principal Investigator
Bülent Ecevit University Faculty of Dentistry
Şeyma Bozkurt Doğan, DDS
Study Chair
Bülent Ecevit University Faculty of Dentistry
Figen Öngöz Dede, DDS
Principal Investigator
Bülent Ecevit University Faculty of Dentistry
Erdim Sertoğlu, MD, DDS
Principal Investigator
Gülhane Military Medical Academy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials